OncoLize
"Treating Tumors from the Inside"
70x – 170x stronger local exposure of the tumor
Reducing chemo levels up to 1000 times to the rest of the body
Can deliver almost anywhere in the body
Wide range of drugs suitable for this local delivery platform
Affordable treatment
For clinicians and medical users
The most direct way of targeting tumors, and still minimally invasive
For clinicians and medical users
Dealing with primary tumors or metastasized tumors posing an immediate threat to vital functions can be a major challenge in managing tumor disease and the well-being of your patients. Our injectable drug depots target the tumor in the most direct manner possible: injecting a drug depot inside the tumor mass.
Investors
This is a magnificent opportunity for reward and for impact in oncology.
Investors
This is a magnificent opportunity for reward and for impact in oncology. You have heard it all before, we are sure of that. So, we derisked the ChemoGell™ proposition to a considerable length and kept it attractive to step in early and make your ROI count. Even better, we are goint to prove this to you with our led product ChemGem to deal with one of the most notorious cancers ut there: Pancreatic cancer, more specifically PDAC.
For Pharma, Biotech and strategic Partners
Direct delivery, as targeted as your drug discovery will ever be…
For Pharma, Biotech and strategic Partners
(After having identified and developed a new oncology drug), With your new oncology drug candidate you need to deliver your asset where it makes most sense, and at the most optimal price point… In many cases we see major opportunities for advanced delivery in, or near, the tumor mass that you target.
For patients and public
Turning drug delivery in oncology upside down, treating Tumors from the Inside
For patients and public
What if we can turn oncology drug delivery upside down? To deliver oncology drugs locally, inside the targeted tumors, where they should be. And then keep them there, increase efficacy in eradication of tumors, reduce the serious side effects and the total cost of care?
OncoLize develops injectable drug depots to deliver oncology drugs where they matter most: inside tumors.
OncoLize is preparing for it's first human trials in pancreatic cancers and other aggressive tumor indications
We localize the delivery of well-proven drugs inside the tumor.
This concentrates drugs where they should be. With effective tumor eradication, reduction of side-effects, and keeping it Triple A: Affordable and Accessible for All.
We have shown the concept to work
We have shown the concept to work in relevant animal models, we have first patents granted and in advanced national stages and we can scale-up these products at minimal costs. With our extensive experience in setting-up controlled delivery start-up’s we aim to start clinical trials in 2028.
At OncoLize we believe and practice that our products should have impact for global issues. We will make these products available for campaigns in Low- and Middle Income Countries through focused NGO-collaborations.
CEO & Founder
We believe that everybody should have access to the best possible care for these aggressive tumor diseases.
We are certain that this can be done by localizing generic drugs and novel drugs alike, with much better effect, far less side-effects, and at much lower costs to patients and the national healthcare systems alike.
NEWS
Things happening
with OncoLize and its partners
Our developments reported by the press
Intratumoral delivery of a thermoresponsive gemcitabine-loaded hydrogel
in preclinical PDAC models
18th July 2026
In our long-standing collaboration with Leiden University Medical Centre (LUMC) our ChemoGell™ was combined with the standard-of-care drug gemcitabine, (ChemGem™), and the product was injected directly into tumors in a standard mouse model for Pancreatic Cancer (PDAC).
OncoLize pitching at RESI, PODD and Bio Europe to treat pancreatic cancer
12th September 2024
Pharma-tech OncoLize is pitching its recent successes in pre-clinical pancreatic cancer treatment at RESI , PODD and Bio-Europe to complete its seed round with €1.5 million in order to finalize its safety and tox studies, scale-up to cGMP grade and preprare for Clinical Trial Application.
15th August 2024
The base patents covering the ChemoGellTM platform has been granted by USPTO, China PTO and JPTO. These broad base patents describe the composition-of-matter and various formulations and applications essential to the oncology business.
